{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:59:57Z","timestamp":1787853597921,"version":"build-2784847793"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY13H080002"],"award-info":[{"award-number":["LY13H080002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470307"],"award-info":[{"award-number":["81470307"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13045-017-0516-x","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T13:28:56Z","timestamp":1503062936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"10","author":[{"given":"Guoqing","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,18]]},"reference":[{"key":"516_CR1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","volume":"119","author":"W Stock","year":"2013","unstructured":"Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013;119:90\u20138.","journal-title":"Cancer"},{"key":"516_CR2","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","volume":"28","author":"DA Thomas","year":"2010","unstructured":"Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880\u20139.","journal-title":"J Clin Oncol"},{"key":"516_CR3","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2014-08-596403","volume":"125","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, O'Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015;125:4010\u20136.","journal-title":"Blood"},{"key":"516_CR4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2012.46.2309","volume":"31","author":"S O'Brien","year":"2013","unstructured":"O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31:676\u201383.","journal-title":"J Clin Oncol"},{"key":"516_CR5","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","volume":"102","author":"H Kantarjian","year":"2003","unstructured":"Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379\u201386.","journal-title":"Blood"},{"key":"516_CR6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","volume":"95","author":"S Maury","year":"2010","unstructured":"Maury S, Huguet F, Leguay T, Lacombe F, Maynadie M, Girard S, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010;95:324\u20138.","journal-title":"Haematologica"},{"key":"516_CR7","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","volume":"124","author":"D Hoelzer","year":"2014","unstructured":"Hoelzer D, Walewski J, Dohner H, Viardot A, Hiddemann W, Spiekermann K, et al. Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124:3870\u20139.","journal-title":"Blood"},{"key":"516_CR8","doi-asserted-by":"crossref","unstructured":"Thomas DA, KH JJ, Faderl S, Jabbour E, Konopleva M, et al. Outcomes continue to be favorable for de novo Philadelphia chromosome negative B-lymphoblastic leukemia (ALL) after therapy with hyper-CVAD (with or without rituximab) regimen. Blood. 2012;120(suppl): abstract 3572.","DOI":"10.1182\/blood.V120.21.3572.3572"},{"key":"516_CR9","doi-asserted-by":"crossref","unstructured":"S\u00e9bastien Maury SC, Xavier T, Dominik H, Thibaut L, Fran\u00e7oise H, Patrice C, et al. Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): results of the randomized Graall-R 2005 study. Blood. 2015;126(suppl): abstract 1.","DOI":"10.1182\/blood.V126.23.1.1"},{"key":"516_CR10","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","volume":"375","author":"S Maury","year":"2016","unstructured":"Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044\u201353.","journal-title":"N Engl J Med"},{"key":"516_CR11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-015-0165-x","volume":"8","author":"KR Rai","year":"2015","unstructured":"Rai KR. Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol. 2015 Jul;8:85.","journal-title":"J Hematol Oncol"},{"key":"516_CR12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bjh.13764","volume":"171","author":"A Awasthi","year":"2015","unstructured":"Awasthi A, Ayello J, Van de Ven C, Elmacken M, Sabulski A, Barth MJ, et al. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive\/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Br J Haematol. 2015;171:763\u201375.","journal-title":"Br J Haematol"},{"key":"516_CR13","doi-asserted-by":"crossref","unstructured":"Koji SP, Hagop MK, Deborah AT, Maria RK, Guillermo GM, Rebecca G, et al. Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood 2015;126(suppl): abstract 1295.","DOI":"10.1182\/blood.V126.23.1295.1295"},{"key":"516_CR14","doi-asserted-by":"crossref","unstructured":"Koji SH, Farhad R, Naval D, Tapan MK, Rita BK, Yesid A, et al. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood. 2016;128(suppl): abstract 2783.","DOI":"10.1182\/blood.V128.22.2783.2783"},{"key":"516_CR15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","volume":"34","author":"K Tobinai","year":"2017","unstructured":"Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Adv Ther. 2017;34:324\u201356.","journal-title":"Adv Ther"},{"key":"516_CR16","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","volume":"17","author":"V Blanc","year":"2011","unstructured":"Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011;17:6448\u201358.","journal-title":"Clin Cancer Res"},{"key":"516_CR17","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.2011.39.4403","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma. J Clin Oncol. 2012;30:2776\u201382.","journal-title":"J Clin Oncol"},{"key":"516_CR18","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1078-0432.CCR-12-3613","volume":"19","author":"H Carol","year":"2013","unstructured":"Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MA, et al. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res. 2013;19:1795\u2013805.","journal-title":"Clin Cancer Res"},{"key":"516_CR19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clml.2015.12.004","volume":"16","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, et al. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016;16:139\u201345.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"516_CR20","doi-asserted-by":"crossref","unstructured":"Amir TF, Tanya MT, Maureen MO, Daniel JD, Bijal DS, Todd MC, et al. Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma. Blood. 2014;124(suppl): abstract 963.","DOI":"10.1182\/blood.V124.21.963.963"},{"key":"516_CR21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8:104.","journal-title":"J Hematol Oncol"},{"key":"516_CR22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","volume":"8","author":"G Fan","year":"2015","unstructured":"Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8:130.","journal-title":"J Hematol Oncol"},{"key":"516_CR23","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226\u201333.","journal-title":"Blood"},{"key":"516_CR24","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493\u20138.","journal-title":"J Clin Oncol"},{"key":"516_CR25","first-page":"757","volume":"10","author":"C Jeune Le","year":"2016","unstructured":"Le Jeune C, Thomas X. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia. Drug Des Devel Ther. 2016;10:757\u201365.","journal-title":"Drug Des Devel Ther"},{"key":"516_CR26","doi-asserted-by":"crossref","unstructured":"Nicola GH, Massimiliano B, Albrecht R, Carlos G, Christoph F, Helmut D, et al. Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL). Blood. 2015;126(suppl): abstract 680.","DOI":"10.1182\/blood.V126.23.680.680"},{"key":"516_CR27","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134\u201340.","journal-title":"J Clin Oncol"},{"key":"516_CR28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57\u201366.","journal-title":"Lancet Oncol"},{"key":"516_CR29","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3109\/10428194.2012.754096","volume":"54","author":"J Francis","year":"2013","unstructured":"Francis J, Dharmadhikari AV, Sait SN, Deeb G, Wallace PK, Thompson JE, et al. CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. Leuk Lymphoma. 2013;54:1517\u201320.","journal-title":"Leuk Lymphoma"},{"key":"516_CR30","doi-asserted-by":"crossref","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Rasche L, Dandekar T, et al. Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients. Blood. 2014;124(suppl): abstract 2291.","DOI":"10.1182\/blood.V124.21.2291.2291"},{"key":"516_CR31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","volume":"8","author":"T Kohnke","year":"2015","unstructured":"Kohnke T, Krupka C, Tischer J, Knosel T, Subklewe M. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015;8:111.","journal-title":"J Hematol Oncol"},{"key":"516_CR32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-016-0277-y","volume":"9","author":"W Ma","year":"2016","unstructured":"Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1\/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9:47.","journal-title":"J Hematol Oncol"},{"key":"516_CR33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-015-0205-6","volume":"8","author":"D Fan","year":"2015","unstructured":"Fan D, Li W, Yang Y, Zhang X, Zhang Q, Yan Y, et al. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3\u2009\u00d7\u2009anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells. J Hematol Oncol. 2015 Oct;8:108.","journal-title":"J Hematol Oncol"},{"key":"516_CR34","unstructured":"Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003;9(suppl):3982s\u20133990s."},{"key":"516_CR35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12079-016-0322-1","volume":"10","author":"S Lumb","year":"2016","unstructured":"Lumb S, Fleischer SJ, Wiedemann A, Daridon C, Maloney A, Shock A, et al. Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor. J Cell Commun Signal. 2016;10:143\u201351.","journal-title":"J Cell Commun Signal"},{"key":"516_CR36","doi-asserted-by":"crossref","unstructured":"Raetz EA CM, Borowitz MJ. Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from Children\u2019s Oncology Group (COG) study. Blood. 2011;118(suppl): abstract 573.","DOI":"10.1182\/blood.V118.21.573.573"},{"key":"516_CR37","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.12778","volume":"165","author":"AS Advani","year":"2014","unstructured":"Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, et al. SWOG S0910: a phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukaemia. Br J Haematol. 2014;165:504\u20139.","journal-title":"Br J Haematol"},{"key":"516_CR38","doi-asserted-by":"crossref","unstructured":"Patrice SC, Fran\u00e7oise H, Emmanuel R, Xavier T, Thibaut L, Tony M, et al. Hyper-CVAD plus epratuzumab as salvage regimen for younger relapsed\/refractory CD22+ B acute lymphoblastic leukemia (ALL) patients: results of the Phase 2 Prospective Cheprall Study. Blood. 2016;128(suppl): abstract 4018.","DOI":"10.1182\/blood.V128.22.4018.4018"},{"key":"516_CR39","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ajh.23180","volume":"87","author":"EJ Jabbour","year":"2012","unstructured":"Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012;87:687\u201391.","journal-title":"Am J Hematol"},{"key":"516_CR40","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","volume":"119","author":"H Kantarjian","year":"2013","unstructured":"Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119:2728\u201336.","journal-title":"Cancer"},{"key":"516_CR41","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353.","journal-title":"N Engl J Med"},{"key":"516_CR42","doi-asserted-by":"crossref","unstructured":"Koji SE, Susan MO, Farhad R, Deborah AT, Tapan MK, Guillermo GM, et al. Phase II study of the salvage mini-hyper-CVD in combination with inotuzumab ozogamicin (INO) for adult patients with relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL). Blood. 2016;128(suppl): abstract 1606.","DOI":"10.1182\/blood.V128.22.1606.1606"},{"key":"516_CR43","doi-asserted-by":"crossref","unstructured":"Koji SE, Susan MO, Farhad R, Deborah AT, Tapan MK, Guillermo GM, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia (ALL): interim result of a phase II clinical trial. blood;128(suppl): abstract 588.","DOI":"10.1182\/blood.V128.22.588.588"},{"key":"516_CR44","doi-asserted-by":"crossref","unstructured":"Wendy SB, Gerard L, Ravi V, John CB, Bayard LP, Meir W, et al. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a cancer and leukemia group B study (CALGB 10102). Blood. 2009;114(suppl): abstract 838.","DOI":"10.1182\/blood.V114.22.838.838"},{"key":"516_CR45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/ejh.12154","volume":"91","author":"NC Gorin","year":"2013","unstructured":"Gorin NC, Isnard F, Garderet L, Ikhlef S, Corm S, Quesnel B, et al. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. Eur J Haematol. 2013;91:315\u201321.","journal-title":"Eur J Haematol"},{"key":"516_CR46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","volume":"65","author":"DM Barrett","year":"2014","unstructured":"Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014;65:333\u201347.","journal-title":"Annu Rev Med"},{"key":"516_CR47","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123:2625\u201335.","journal-title":"Blood"},{"key":"516_CR48","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","volume":"13","author":"RJ Brentjens","year":"2007","unstructured":"Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13:5426\u201335.","journal-title":"Clin Cancer Res"},{"key":"516_CR49","doi-asserted-by":"crossref","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","volume":"8","author":"ML Davila","year":"2013","unstructured":"Davila ML, Kloss CC, Gunset G, Sadelain M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One. 2013;8:e61338.","journal-title":"PLoS One"},{"key":"516_CR50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","volume":"9","author":"Y Hu","year":"2016","unstructured":"Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol. 2016;9:70.","journal-title":"J Hematol Oncol"},{"key":"516_CR51","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"516_CR52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet"},{"key":"516_CR53","doi-asserted-by":"crossref","unstructured":"Jae H, Park IR, Wang X, Yvette B, Terence P, Halton E, et al. Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL. Blood. 2015;126(suppl): abstract 682.","DOI":"10.1200\/jco.2015.33.15_suppl.7010"},{"key":"516_CR54","doi-asserted-by":"crossref","unstructured":"Lee DW, Yuan CM, Shah NN, Delbrook C, Yates B, Zhang H, et al. Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine\/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation. Blood. 2016;128(suppl): abstract 218.","DOI":"10.1182\/blood.V128.22.218.218"},{"key":"516_CR55","doi-asserted-by":"crossref","unstructured":"Shah B, Sender LS, Lee DW, Castro JE, Wierda WG, Dietz AC, et al. High rates of minimal residual disease-negative (MRD\u2212) complete responses (CR) in adult and pediatric and patients with relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL) treated with KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cells): preliminary results of the ZUMA-3 and ZUMA-4 trials. Blood. 2016;128(suppl): abstract 2803.","DOI":"10.1182\/blood.V128.22.2803.2803"},{"key":"516_CR56","doi-asserted-by":"crossref","unstructured":"Grupp SA, Shaw PA, Aplenc R, Barrett DM, Callahan C, Lacey SF, et al. Durable remissions in children with relapsed\/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood. 2015;126(suppl): abstract 681.","DOI":"10.1182\/blood.V126.23.681.681"},{"key":"516_CR57","doi-asserted-by":"crossref","unstructured":"Grupp SA, Buechner J, Bittencourt H, Maude SL, Verneris MR, Myers GD, et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL). Blood. 2016;128(suppl): abstract 221.","DOI":"10.1016\/j.clml.2017.07.030"},{"key":"516_CR58","doi-asserted-by":"crossref","unstructured":"Maude SL, Boyer MW, Grupp SA, Davies SM, Phillips CL, Verneris MR, et al. Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed\/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood. 2016;128(suppl): abstract 2801.","DOI":"10.1182\/blood.V128.22.2801.2801"},{"issue":"1","key":"516_CR59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-017-0405-3","volume":"10","author":"J Liu","year":"2017","unstructured":"Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017 Jan;10(1):35.","journal-title":"J Hematol Oncol"},{"key":"516_CR60","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129\u201339.","journal-title":"Blood"},{"key":"516_CR61","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","volume":"122","author":"CR Cruz","year":"2013","unstructured":"Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122:2965\u201373.","journal-title":"Blood"},{"key":"516_CR62","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34:1112\u201321.","journal-title":"J Clin Oncol"},{"key":"516_CR63","doi-asserted-by":"publisher","unstructured":"Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016;108: djv439. doi: 10.1093\/jnci\/djv439","DOI":"10.1093\/jnci\/djv439"},{"key":"516_CR64","doi-asserted-by":"crossref","unstructured":"Smith M, James S, Davila ML, Velardi E, Argyropoulos EV, Gunset G, et al. Murine donor 1928z CAR T cells exert potent graft-versus-lymphoma activity without graft-versus-host-disease. Blood. 2016;128 (suppl): abstract 653.","DOI":"10.1182\/blood.V128.22.653.653"},{"key":"516_CR65","doi-asserted-by":"crossref","unstructured":"Cai B, Guo M, Wang Y, Zhang Y, Yang J, Guo Y, et al. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. J Hematol Oncol. 2016;9(1):131.","DOI":"10.1186\/s13045-016-0357-z"},{"key":"516_CR66","doi-asserted-by":"crossref","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"516_CR67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MOP.0000000000000043","volume":"26","author":"DM Barrett","year":"2014","unstructured":"Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr. 2014;26:43\u20139.","journal-title":"Curr Opin Pediatr"},{"key":"516_CR68","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318.","journal-title":"N Engl J Med"},{"key":"516_CR69","first-page":"1","volume":"14","author":"Dummy","year":"2016","unstructured":"Dummy. From CARs to TRUCKs and beyond: safely en route to adoptive T-cell therapy for cancer. EBio Medicine. 2016;14:1\u20132.","journal-title":"EBio Medicine"},{"key":"516_CR70","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017\u201323.","journal-title":"Blood"},{"key":"516_CR71","doi-asserted-by":"crossref","unstructured":"Gardner R, Smithers H, Leger KJ, Annesley CE, Summers C, Brown C, et al. CD19CAR T cell products of defined CD4:CD8 composition and transgene expression show prolonged persistence and durable MRD-negative remission in pediatric and young adult B-cell ALL. Blood. 2016;128(suppl): abstract 219.","DOI":"10.1200\/JCO.2016.34.15_suppl.3048"},{"key":"516_CR72","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123\u201338.","journal-title":"J Clin Invest"},{"key":"516_CR73","doi-asserted-by":"crossref","unstructured":"Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C, et al. Durable remissions in children with relapsed\/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood. 2015;126(suppl): abstract 681.","DOI":"10.1182\/blood.V126.23.681.681"},{"key":"516_CR74","doi-asserted-by":"crossref","unstructured":"Maude SL, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Baniewicz D, et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory acute lymphoblastic leukemia. Blood. 2016;128 (suppl): abstract 217.","DOI":"10.1182\/blood.V128.22.217.217"},{"key":"516_CR75","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/mt.2014.148","volume":"22","author":"J Corrigan-Curay","year":"2014","unstructured":"Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, et al. T-cell immunotherapy: looking forward. Mol Ther. 2014;22:1564\u201374.","journal-title":"Mol Ther"},{"key":"516_CR76","doi-asserted-by":"crossref","unstructured":"Maude SL, Hucks GE, Seif AE, Talekar MK, Teachey DT, Baniewicz D, et al. The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). J Clin Oncol. 2017;35(suppl): abstract 103.","DOI":"10.1200\/JCO.2017.35.15_suppl.103"},{"key":"516_CR77","doi-asserted-by":"crossref","unstructured":"Gill S, Frey NV, Hexner EO, Lacey SF, Melenhorst JJ, Byrd JC, et al. CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. J Clin Oncol. 2017;35(suppl): abstract 7509.","DOI":"10.1200\/JCO.2017.35.15_suppl.7509"},{"key":"516_CR78","doi-asserted-by":"crossref","unstructured":"Lacey SF, Xu J, Ruella M. Cars in leukemia: relapse with antigen-negative leukemia originating from a single B cell expressing the leukemia-targeting CAR. Blood 2016, 128 (suppl): abstract 281;","DOI":"10.1182\/blood.V128.22.281.281"},{"key":"516_CR79","doi-asserted-by":"crossref","first-page":"e23621","DOI":"10.4161\/onci.23621","volume":"2","author":"AH Long","year":"2013","unstructured":"Long AH, Haso WM, Orentas RJ. Lessons learned from a highly-active CD22-specific chimeric antigen receptor. Oncoimmunology. 2013;2:e23621.","journal-title":"Oncoimmunology"},{"key":"516_CR80","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121:1165\u201374.","journal-title":"Blood"},{"key":"516_CR81","doi-asserted-by":"crossref","unstructured":"Shah nn, Yuan CM, Shalabi H, Yates B, Delbrook C, Zhang L, et al. Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL). Blood. 2016;128(suppl): abstract 650.","DOI":"10.1182\/blood.V128.22.650.650"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-017-0516-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T10:40:36Z","timestamp":1719398436000},"score":1,"resource":{"primary":{"URL":"http:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-017-0516-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,18]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1186\/s13045-017-0516-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,18]]},"article-number":"150"}}